Neurocrine Biosciences Inc (NBIX)

Net profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	249,700	191,000	176,400	64,000	154,500	58,200	12,200	71,400	89,600	444,800	364,700	402,000	407,300	93,400	204,800	176,500	37,000	21,078	18,042	-39,171
Revenue (ttm)	US$ in thousands	1,882,900	1,779,300	1,668,300	1,522,900	1,411,600	1,306,100	1,208,800	1,185,500	1,107,700	1,050,200	1,010,800	1,022,200	1,020,900	1,017,010	981,066	862,604	764,254	651,736	581,765	503,032
Net profit margin		13.26%	10.73%	10.57%	4.20%	10.95%	4.46%	1.01%	6.02%	8.09%	42.35%	36.08%	39.33%	39.90%	9.18%	20.88%	20.46%	4.84%	3.23%	3.10%	-7.79%

December 31, 2023 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $249,700K ÷ $1,882,900K
= 13.26%

Neurocrine Biosciences, Inc.'s net profit margin has exhibited fluctuating trends over the past eight quarters. The company's net profit margin ranged from a low of 0.94% in Q2 2022 to a high of 13.23% in Q4 2023. The significant variability in the net profit margin suggests varying levels of profitability and efficiency in cost management.

The trend shows an improvement in profitability over the quarters, as evidenced by the increasing values from Q1 2022 to Q4 2023. This could indicate that Neurocrine Biosciences, Inc. has been effectively managing its expenses and increasing profitability over time. However, the dip observed in Q1 2023 and Q2 2023 should be monitored closely for any emerging trends or factors impacting the company's profitability.